Bo Chen, PhD Email Bo Chen
- ASSOCIATE PROFESSOR | Ophthalmology
- ASSOCIATE PROFESSOR | Neuroscience
- ASSOCIATE PROFESSOR | Cell, Developmental & Regenerative Biology
Axonal Growth and Degeneration, Neuro-degeneration/protection, Neuronal Regeneration, Neuroscience
PhD, University of Miami
Postdoc, Harvard Medical School
Pew Scholar in the Biomedical Sciences
The Pew Charitable Trusts
Neural Degeneration and Regeneration in the Mammalian Retina
We are currently recruiting motivated postdoctoral researchers and students to join our research adventures. The main research interests of my laboratory focus on the mechanistic and therapeutic studies of neurodegenerative diseases in the retina resulting in vision impairment and blindness. We study signaling pathways and gene expression network in retinal neurons in normal and diseased conditions, with an ultimate aim to save vision. Neuroprotection and neuroregeneration are the two main strategies we use to prevent the death of existing neurons or to generate new neurons. 1. For neuroprotection, we investigate molecular mechanisms underlying the degeneration of photoreceptors, the primary sensory neurons that mediate the first step in vision, and ganglion cells, the output neurons of the retina. An in-depth understanding the signaling pathways that are perturbed in a diseased retina will facilitate the design of therapeutic strategies to protect photoreceptors and ganglion cells through modulation of the components of the affected pathways. 2. For neural regeneration, we examine the intrinsic signaling pathways and transcription control in Müller glial cells, the primary glial cell type in the retina, in order to reprogram them in vivo to generate adult retinal stem cells that are capable of differentiating to retinal neurons. 3. In addition, my laboratory is also actively exploring strategies to promote axon regeneration using optic nerve crush to model CNS (central nervous system) injury.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Chen did not report having any of the following types of financial relationships with industry during 2019 and/or 2020: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.